Several targeted therapies have already been approved by the FDA for the treatment of cancer, and the number will likely increase as research continues to take place. The targeted therapies listed below are approved by the FDA for specific cancer indications. These drugs continue to be studied in clinical trials for various types of cancer. For each generic drug name listed, the brand name is shown in parentheses.
- Alemtuzumab (Campath®)
- Anastrozole (Arimidex®)
- Bevacizumab (Avastin®)
- Bortezomib (Velcade®)
- Cetuximab (Erbitux®)
- Dasatinib (Sprycel®)
- Erlotinib Hydrochloride (Tarceva®)
- Exemestane (Aromasin®)
- Fulvestrant (Faslodex®)
- Gefitinib (Iressa®)
- Gemtuzumab Ozogamicin (Mylotarg®)
- Ibritumomab Tiuxetan (Zevalin®)
- Imatinib Mesylate (Gleevec®)
- Lapatinib Ditosylate (Tykerb®)
- Letrozole (Femara®)
- Nilotinib (Tasigna®)
- Panitumumab (Vectibix®)
- Rituximab (Rituxan®)
- Sorafenib Tosylate (Nexavar®)
- Sunitinib Malate (Sutent®)
- Tamoxifen
- Temsirolimus (Torisel®)
- Toremifene (Fareston®)
- Tositumomab and 131I-tositumomab (Bexxar®)
- Trastuzumab (Herceptin®)
Additional information about FDA approvals for these drugs can be found in the Drug Information Summaries.
